IDEAL IMPLANT核心试验:新型激励模式提高美容外科随访率
该研究针对IDEAL IMPLANT乳房假体核心试验,采用独立不可撤销信托的激励支付模式:每位受试者入组时存入3500美元,完成全部随访者最终分享信托资金。502名受试者的5年随访率在初次和修复隆乳队列分别为94.9%和96.7%,高于其他FDA标准化随访报告的假体试验。
要点
- 入组时每人存入3500美元至独立信托,完成全部随访者最终分享资金。
- IDEAL IMPLANT核心试验5年随访率初次隆乳94.9%、修复隆乳96.7%。
- 该随访率高于MemoryShape、Allergan 410和Sientra核心试验的FDA报告数据。
核心结论
- 新型激励支付策略可最大化美容外科患者随访率,为未来试验提供更完整数据。
研究设计与样本
- IDEAL IMPLANT核心试验纳入502名受试者,入组时每人向独立不可撤销信托存入3500美元并投资于多元化组合。
主要发现
- 初次隆乳队列5年随访率为94.9%,修复隆乳队列为96.7%。
- 上述随访率高于所有其他采用FDA标准化随访报告的现有乳房假体核心试验(MemoryShape、Allergan 410、Sientra)。
关键数值与推荐
- 错过随访即退出研究,受试者获已完成访视的补偿,其余信托份额留在信托中。
- 10年研究结束时,信托资金将分配给完成所有 required 随访访视的受试者。
临床怎么用
- 美容外科临床试验可考虑采用有条件的经济激励(完成全部随访后分享信托资金)以提高随访率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High follow-up rates are critical for robust research with minimal bias, and are particularly important for breast implant Core Studies seeking U.S. Food and Drug Administration approval. The Core Study for IDEAL IMPLANT, the most recently U.S. Food and Drug Administration-approved breast implant, used a novel incentive payment model to achieve higher follow-up rates than in previous breast implant trials. METHODS: At enrollment, $3500 was deposited into an independent, irrevocable trust for each of the 502 subjects and invested in a diversified portfolio. If a follow-up visit is missed, the subject is exited from the study and compensated for completed visits, but the remainder of her share of the funds stay in the trust. At the conclusion of the 10-year study, the trust will be divided among those subjects who completed all required follow-up visits. For primary and revision augmentation cohorts, the U.S. Food and Drug Administration published follow-up rates from Core Studies were compared for all currently available breast implants. RESULTS: Five-year follow-up rates for the IDEAL IMPLANT Core Study are higher for both primary augmentation and revision augmentation cohorts (94.9 percent and 96.7 percent, respectively) when compared to all other trials that have used U.S. Food and Drug Administration standardized follow-up reporting (MemoryShape, Allergan 410, and Sientra Core Studies). CONCLUSIONS: This trial demonstrates the utility of a novel incentive strategy to maximize follow-up in cosmetic surgery patients. This strategy may benefit future cosmetic surgery trials and perhaps any prospective research trial by providing more complete data. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
引用
- Mueller MA, Nichter LS, Hamas RS, et al. Novel Approach for Maximizing Follow-Up in Cosmetic Surgery Clinical Trials: The Ideal Implant Core Trial Experience. Plast Reconstr Surg. 2017. PMID: 28609349. doi:10.1097/PRS.0000000000003666
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。